Psychopharmacology of Parkinson's Disease and Movement Disorders
This quiz covers the psychopharmacology of Parkinson's disease and movement disorders, including the mechanisms of action, clinical uses, and adverse effects of various medications used in the treatment of these conditions.
Questions
Which of the following is the primary neurotransmitter affected in Parkinson's disease?
- Dopamine
- Serotonin
- Noradrenaline
- GABA
What is the most commonly used medication for the treatment of Parkinson's disease?
- Levodopa
- Carbidopa
- Pramipexole
- Ropinirole
What is the role of carbidopa in the treatment of Parkinson's disease?
- It reduces the peripheral conversion of levodopa to dopamine.
- It enhances the penetration of levodopa into the brain.
- It reduces the adverse effects of levodopa.
- It prolongs the duration of action of levodopa.
Which of the following is a dopamine agonist used in the treatment of Parkinson's disease?
- Pramipexole
- Ropinirole
- Amantadine
- Selegiline
What is the mechanism of action of amantadine in the treatment of Parkinson's disease?
- It increases the release of dopamine from presynaptic neurons.
- It blocks the reuptake of dopamine into presynaptic neurons.
- It inhibits the metabolism of dopamine.
- It protects dopaminergic neurons from degeneration.
Which of the following is a MAO-B inhibitor used in the treatment of Parkinson's disease?
- Selegiline
- Rasagiline
- Pramipexole
- Ropinirole
What is the mechanism of action of COMT inhibitors in the treatment of Parkinson's disease?
- They increase the release of dopamine from presynaptic neurons.
- They block the reuptake of dopamine into presynaptic neurons.
- They inhibit the metabolism of dopamine.
- They protect dopaminergic neurons from degeneration.
Which of the following is a common adverse effect of levodopa therapy in Parkinson's disease?
- Nausea and vomiting
- Dyskinesias
- Hallucinations
- Orthostatic hypotension
What is the term used to describe the phenomenon of decreased effectiveness of levodopa over time in Parkinson's disease?
- Tardive dyskinesia
- Wearing-off effect
- Rebound effect
- Augmentation
Which of the following is a potential strategy to manage the wearing-off effect of levodopa in Parkinson's disease?
- Increasing the dose of levodopa
- Adding a dopamine agonist
- Using a MAO-B inhibitor
- Using a COMT inhibitor
What is the term used to describe the phenomenon of involuntary movements that occur in the absence of levodopa therapy in Parkinson's disease?
- Tardive dyskinesia
- Wearing-off effect
- Rebound effect
- Augmentation
Which of the following is a potential strategy to manage the rebound effect in Parkinson's disease?
- Reducing the dose of levodopa
- Adding a dopamine agonist
- Using a MAO-B inhibitor
- Using a COMT inhibitor
What is the term used to describe the phenomenon of increased effectiveness of levodopa over time in Parkinson's disease?
- Tardive dyskinesia
- Wearing-off effect
- Rebound effect
- Augmentation
Which of the following is a potential strategy to manage augmentation in Parkinson's disease?
- Increasing the dose of levodopa
- Adding a dopamine agonist
- Using a MAO-B inhibitor
- Using a COMT inhibitor
What is the term used to describe the phenomenon of involuntary movements that occur in response to a sudden reduction in the dose of levodopa in Parkinson's disease?
- Tardive dyskinesia
- Wearing-off effect
- Rebound effect
- Withdrawal dyskinesia